## CLAIMS

What is claimed is:

1. A pharmaceutical composition, comprising:
   a) about 1,800 mg of an anti-CD38 antibody, wherein the anti-CD38 antibody is of IgG1 isotype and comprises:
      i) a heavy chain variable region (VH) of SEQ ID NO: 4; and
      ii) a light chain variable region (VL) of SEQ ID NO: 5; and
   b) rHuPH20 recombinant hyaluronidase,
   wherein the pharmaceutical composition has a hyaluronidase enzymatic activity of about 30,000 U.

2. The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 1, further comprising from about 5 mM to about 10 mM histidine.

4. The pharmaceutical composition of claim 1, further comprising about 8 mM histidine.

5. The pharmaceutical composition of claim 1, further comprising from about 0.1 mg/mL to about 2.5 mg/mL methionine.

6. The pharmaceutical composition of claim 1, further comprising methionine at a concentration of about 1 mg/mL.

7. The pharmaceutical composition of claim 1, further comprising from about 100 mM to about 300 mM sorbitol.

8. The pharmaceutical composition of claim 1, further comprising about 270 mM sorbitol.

9. The pharmaceutical composition of claim 1, further comprising from about 0.01% w/v to about 0.1% w/v polysorbate-20 (PS-20).

10. The pharmaceutical composition of claim 1, further comprising from about 0.01% w/v to about 0.04% w/v PS-20.

11. The pharmaceutical composition of claim 1, further comprising about 0.04% w/v PS-20.

12. The pharmaceutical composition of claim 1, further comprising:
    a) from about 5 mM to about 10 mM histidine;
    b) from about 0.1 mg/mL to about 2.5 mg/mL methionine;
    c) from about 100 mM to about 300 mM sorbitol; and
    d) from about 0.01% w/v to about 0.1% w/v PS-20.

13. The pharmaceutical composition of claim 1, further comprising:
    a) from about 5 mM to about 10 mM histidine;
    b) from about 0.1 mg/mL to about 2.5 mg/mL methionine;
    c) from about 100 mM to about 300 mM sorbitol; and
    d) from about 0.01% w/v to about 0.04% w/v PS-20.

14. The pharmaceutical composition of claim 1, further comprising:
    a) about 8 mM histidine;
    b) about 1 mg/mL methionine;
    c) about 270 mM sorbitol; and
    d) about 0.04% w/v PS-20.

15. 15 A pharmaceutical composition, comprising:
    a) about 1,800 mg of an anti-CD38 antibody, wherein the anti-CD38 antibody is of IgG1 isotype and comprises:
        i) a heavy chain of SEQ ID NO: 12; and
        ii) a light chain of SEQ ID NO: 13; and
    b) rHuPH20 recombinant hyaluronidase,

    wherein the pharmaceutical composition has a hyaluronidase enzymatic activity of about 30,000 U.

16. The pharmaceutical composition of claim 15, further comprising a pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 15, further comprising:

a) from about 5 mM to about 10 mM histidine;

b) from about 0.1 mg/mL to about 2.5 mg/mL methionine;

c) from about 100 mM to about 300 mM sorbitol; and

d) from about 0.01% w/v to about 0.1% w/v PS-20.

18. The pharmaceutical composition of claim 15, further comprising:

a) from about 5 mM to about 10 mM histidine;

b) from about 0.1 mg/mL to about 2.5 mg/mL methionine;

c) from about 100 mM to about 300 mM sorbitol; and

d) from about 0.01% w/v to about 0.04% w/v PS-20.

19. The pharmaceutical composition of claim 15, further comprising:

a) about 8 mM histidine;

b) about 1 mg/mL methionine;

c) about 270 mM sorbitol; and

d) about 0.04% w/v PS-20.

20. The pharmaceutical composition of claim 15, further comprising a buffer.

21. The pharmaceutical composition of claim 20, further comprising from about 100 mM to about 300 mM of a saccharide.

22. The pharmaceutical composition of claim 21, wherein the saccharide is sorbitol.

23. The pharmaceutical composition of claim 2, further comprising about 0.04% w/v polysorbate-20.

24. The pharmaceutical composition of claim 23, further comprising from about 0.1 mg/mL to about 2.5 mg/mL methionine.

25. The pharmaceutical composition of claim 24, wherein the pharmaceutical composition is at pH 5.3 to 5.8.

26. The pharmaceutical composition of claim 25, wherein the pharmaceutical composition is at pH about 5.5.

27. The pharmaceutical composition of claim 21, wherein the saccharide is trehalose.

28. The pharmaceutical composition of claim 27, further comprising about 0.04% w/v polysorbate-20.

29. The pharmaceutical composition of claim 28, further comprising from about 0.1 mg/mL to about 2.5 mg/mL methionine.

30. The pharmaceutical composition of claim 29, wherein the pharmaceutical composition is at pH 5.3 to 5.8.

31. The pharmaceutical composition of claim 30, wherein the pharmaceutical composition is at pH about 5.5.

32. The pharmaceutical composition of claim 15, further comprising from about 5 mM to about 50 mM of histidine.

33. The pharmaceutical composition of claim 32, further comprising from about 100 mM to about 300 mM of a saccharide.

34. The pharmaceutical composition of claim 33, wherein the saccharide is sorbitol.

35. The pharmaceutical composition of claim 34, further comprising about 0.04% w/v polysorbate-20.

36. The pharmaceutical composition of claim 35, further comprising from about 0.1 mg/mL to about 2.5 mg/mL methionine.

37. The pharmaceutical composition of claim 36, wherein the pharmaceutical composition is at pH 5.3 to 5.8.

38. The pharmaceutical composition of claim 37, wherein the pharmaceutical composition is at pH about 5.5.

39. The pharmaceutical composition of claim 33, wherein the saccharide is trehalose.

40. The pharmaceutical composition of claim 39, further comprising about 0.04% w/v polysorbate-20.

41. The pharmaceutical composition of claim 40, further comprising from about 0.1 mg/mL to about 2.5 mg/mL methionine.

42. The pharmaceutical composition of claim 61, wherein the pharmaceutical composition is at pH 5.3 to 5.8.

43. The pharmaceutical composition of claim 62, wherein the pharmaceutical composition is at pH about 5.5.

44. The pharmaceutical composition of claim 15, wherein the anti-CD38 antibody is at a concentration of:

a) from about 10 mg/mL to about 180 mg/mL;
b) from about 20 mg/mL to about 160 mg/mL;
c) from about 20 mg/mL to about 140 mg/mL;
d) from about 20 mg/mL to about 120 mg/mL;
e) from about 40 mg/mL to about 120 mg/mL;
f) from about 60 mg/mL to about 120 mg/mL;
g) from about 80 mg/mL to about 120 mg/mL; or
h) from about 100 mg/mL to about 120 mg/mL.

45. The pharmaceutical composition of claim 15, wherein the anti-CD38 antibody is at a concentration of from about 100 mg/mL to about 120 mg/mL.

46. The pharmaceutical composition of claim 15, wherein the anti-CD38 antibody is at a concentration of about 20 mg/mL.

47. The pharmaceutical composition of claim 15, wherein the anti-CD38 antibody is at a concentration of about 100 mg/mL.

48. The pharmaceutical composition of claim 15, wherein the anti-CD38 antibody is at a concentration of about 120 mg/mL.